



We are a technology leader in decentralized genetic testing.

Ulisse Biomed S.p.A. is an Italian public company with an established footprint of global stakeholders. We have operations and laboratories in Milan and Trieste (Italy), with a sales track record in more than 20 countries worldwide in the last 10 years.



A large and growing number of health and environmental threats are monitored and diagnosed by genetic testing

Pope Francis remains in critical condition, Vatican says

Pontiff had fallen into critical condition, receiving high flows of oxygen and blood transfusions in hospital as he battles complex lung infection

Why California declared a state of emergency over bird flu

The virus has spread for years in wild birds and commercial poultry, and was detected for the first time in US dairy cattle in March

nature medicine

The microbiome, cancer, and cancer therapy

Beth A. Helmink, M. A. Wadud Khan, Amanda Hermann, Vancheswaran Gopalakrishnan & Jennifer A. Warqo ☑

Global leaders set first targets to control antimicrobial resistance crisis


Ferrero finds Salmonella again at Belgian factory

We enable decentralised genetic testing anywhere at any time, with real-time Al-enabled analytics

We leverage a unique array of vertically integrated patented technologies with top-notch performance in each component of the system.

We hold patents in US, Europe and China for our proprietary technology.

We work in compliance with various quality certifications for medical device manufacturing, cloud privacy, cybersecurity, and security in cloud.




There is an under-served market area for mid to low testing volumes

Our technology provides to distributed locations with mid to low testing volume the same performance and cost efficiency of much larger laboratories.

Typical low testing throughput technologies have very high costs compared to the other technologies used in laboratories with high test turnover.

Our technology enables medium&small labs to access similar cost efficiency of big central labs, with no compromises in performance.



We immensely appreciate the trust that our global leader partners demonstrate in our scientific and diagnostic solutions



Gates Foundation



In September 2020, our solution has been approved by Health Canada for Point-Of-Care COVID distributed testing.

The most challenging regulatory approval to obtain, the three holders of an equivalent certification at that time being Abbott Laboratories, Cepheid and Roche.

The Hyris platform for distributed genetic testing has been selected by The Gates Foundation and the Malaria Institute at Johns Hopkins University as the best technology for malaria surveillance in remote areas.

During the last 6 years the technology has been successfully piloted and is now being deployed in 30 locations in West Africa. Expansion to other countries and for other health threats is in planning stages.

We immensely appreciate the trust that our global leader partners demonstrate in our scientific and diagnostic solutions









In partnership with the Icahn School of Medicine at Mount Sinai (NY) and Duke NUS Medical School (Singapore), we developed a test to diagnose long-term cellular immune response to infections.

The research results has been published in Nature Biotechnology. The COVID immune response test has been used by the EU program "Vaccelerate" to monitor vaccine strategy and execution and also by the Spanish Government for a national epidemiological study on SARS-CoV-2 population protection.

Synlab, the biggest laboratory chain in Europe, is a client of test catalog for liquid cancer detection and other oncology-related genetic mutations.

